Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022 Featuring Astellas Pharma, Pfizer, Allergan, , Merck & Co., Mylan, Teva Pharma and Ferring Pharma - ResearchAndMarkets.com

DUBLIN--()--The "Drugs for Urinary Incontinence and Overactive Bladder: Global Markets to 2022" report has been added to ResearchAndMarkets.com's offering.

This research report categorizes the drugs for urinary incontinence and overactive bladder by type. Product type include Idiopathic Bladder Overactivity, and Neurogenic Bladder Overactivity.

Report Includes:

  • 96 data tables.
  • An overview of the global market for drugs for urinary incontinence and overactive bladder
  • Analyses of global market trends, with data from 2013 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Coverage of types of urinary incontinence such as urge incontinence (UUI), stress incontinence (SUI), overflow incontinence (OUI), functional incontinence (FUI), and mixed symptoms (MUI)
  • Identification of effective treatment options for incontinence and overactive bladder
  • Analyses of Idiopathic bladder overactivity and neurogenic bladder overactivity and their probable causes
  • Detailed profiles of key competitors of the market, including Astellas Pharma Inc., Pfizer, Inc., Allergan, PLC., Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals A/S

Key Topics Covered:

1 Introduction

2 Summary and Highlights

3 Drugs for Urinary Incontinence and Overactive Bladder Market Characteristics

4 Drugs for Urinary Incontinence and Overactive Bladder Market Size and Growth

5 Drugs for Urinary Incontinence and Overactive Bladder Market Trends and Strategies

6 PESTLE Analysis

7 Drugs for Urinary Incontinence and Overactive Bladder Market Segmentation

8 Drugs for Urinary Incontinence and Overactive Bladder Market: Regional and Country Analyses

9 Drugs for Urinary Incontinence and Overactive Bladder Market Customer Information

10 Global Drugs for Urinary Incontinence and Overactive Bladder Market Comparison with Macro Economic Factors

11 Asia-Pacific Drugs for Urinary Incontinence and Overactive Bladder Market

12 Asia-Pacific Drugs for Urinary Incontinence and Overactive Bladder Market: Country Analysis

13 Western Europe Drugs for Urinary Incontinence and Overactive Bladder Market

14 UK Drugs for Urinary Incontinence and Overactive Bladder Market: Country Analysis

15 Eastern Europe Drugs for Urinary Incontinence and Overactive Bladder Market

16 Eastern Europe Drugs for Urinary Incontinence and Overactive Bladder Market: Country Analysis

17 North America Drugs for Urinary Incontinence and Overactive Bladder Market

18 North America Drugs for Urinary Incontinence and Overactive Bladder Market: Country Analysis

19 South America Drugs for Urinary Incontinence and Overactive Bladder Market

20 South America Drugs for Urinary Incontinence and Overactive Bladder Market: Country Analysis

21 Middle East Drugs for Urinary Incontinence and Overactive Bladder Market

22 Africa Drugs for Urinary Incontinence and Overactive Bladder Market

23 Drugs for Urinary Incontinence and Overactive Bladder Market: Competitive Landscape

24 Key Mergers and Acquisitions in the Drugs for Urinary Incontinence and Overactive Bladder Market

25 Appendix

Companies Mentioned

  • Allergan Plc
  • Astellas Pharma Inc.
  • Merck & Company, Inc.
  • Mylan N.V.
  • Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/t3lxx2/drugs_for_urinary?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Urological Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Urological Disorders Drugs